Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

<p>Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Erwin Tomasich (15052256) (author)
Rannpháirtithe:	Ariane Steindl (15022655) (author), Christina Paiato (15360180) (author), Teresa Hatziioannou (15052262) (author), Markus Kleinberger (15360183) (author), Luzia Berchtold (15360186) (author), Rainer Puhr (15052253) (author), Johannes A. Hainfellner (15360189) (author), Leonhard Müllauer (15118769) (author), Georg Widhalm (15052268) (author), Franziska Eckert (15360192) (author), Rupert Bartsch (15360195) (author), Gerwin Heller (15052250) (author), Matthias Preusser (15017558) (author), Anna Sophie Berghoff (15360198) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Breast Cancer Clinical-Stage Research Drug Targets Cell surface receptor drug targets Lung Cancer Progression, Invasion & Metastasis Metastasis
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
de réir: Erwin Tomasich (15052256)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
de réir: Niklas Klümper (15048887)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
de réir: Yuncheng Bei (16546095)
Foilsithe / Cruthaithe: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
de réir: Sheheryar Kabraji (15050565)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
de réir: Santiago Duro-Sánchez (14959182)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
de réir: Martina S.J. McDermott (15206951)
Foilsithe / Cruthaithe: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
de réir: Srivandana Akshintala (16610490)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
de réir: Srivandana Akshintala (16610490)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
de réir: Feng Wang (44414)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
de réir: Feng Wang (44414)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
de réir: Feng Wang (44414)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
de réir: Feng Wang (44414)
Foilsithe / Cruthaithe: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
de réir: Katie E. Hebron (15046889)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3c48p9klsfa2hb3da5ds29a6be